Cardiff Oncology Highlights Onvansertib Data with KOL Webinar
Event summary
- Cardiff Oncology will host a webinar on April 30, 2026, featuring KOL Mrinal Patnaik.
- The webinar will focus on data from an investigator-initiated trial of onvansertib as a single agent in chronic myelomonocytic leukemia (CMML).
- Mrinal Patnaik leads the Acute Leukemia and Myeloid Neoplasms group and Epigenomics Program at Mayo Clinic.
- Onvansertib is Cardiff Oncology’s lead asset, a PLK1 inhibitor currently in Phase 2 trials for mCRC.
The big picture
Cardiff Oncology’s focus on PLK1 inhibition represents a targeted approach to cancer treatment, aiming to overcome resistance mechanisms. The webinar highlights the company’s efforts to expand onvansertib’s application beyond its primary mCRC indication, a common strategy for clinical-stage biotech firms seeking to broaden market opportunity and de-risk their pipelines. The reliance on KOLs to present data underscores the importance of external validation in the competitive oncology landscape.
What we're watching
- Clinical Efficacy
- The webinar’s data presentation will be crucial in assessing onvansertib’s potential beyond its current mCRC focus, particularly given its reported activity in hard-to-treat tumors.
- KOL Influence
- Mr. Patnaik’s prominence in myeloid neoplasms research suggests the webinar aims to bolster confidence in onvansertib’s clinical utility and potentially attract further investment.
- Trial Adoption
- The reliance on investigator-initiated trials indicates Cardiff Oncology’s strategy for expanding onvansertib’s indications, and the pace of enrollment and data maturation in these trials will dictate the drug’s broader development timeline.
Related topics